
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has demonstrated significant growth in its surgical and chronic wound care product lines, with surgical soft tissue repair products increasing 24% year-over-year to $23.4 million, driven predominantly by the demand for CellerateRX Surgical. The company has implemented an effective strategy to expand its distribution network and healthcare facility partnerships, which could further enhance its revenue growth trajectory. Additionally, the anticipation of profitability in the third quarter of 2025 underscores a positive shift in financial stability and operational efficiency for Sanara MedTech.
Bears say
Sanara MedTech reported net revenue of $26.3 million, marking a 21.5% year-over-year growth that fell slightly short of projections. The company faces significant risks including lower-than-anticipated revenue growth, challenges in securing new customers, difficulties in launching new products or services, and the potential for dilution. Additionally, the reduction of the enterprise value to revenue multiple from 4.3x to 3.0x indicates a declining market sentiment, particularly in light of telehealth no longer being part of the business strategy.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares